# Oncolytics Biotech Inc. (ONCY)

> Source: Nexqual · https://nexqual.com/ONCY · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Oncolytics Biotech Inc. (ONCY), nexqual.com/ONCY" · informational, not investment advice.

**Price:** USD 0.55 (+1.75% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.54 · day 0.52–0.59 · 52w 0.44–1.32 · market cap $71.8M · NCM

## Key facts
- Analysts: Buy (mean 1.67 on a 1–5 scale) (6 analysts), mean target USD 4.17 (range 2.86–5.88).
- Total return with dividends: 1Y -53.0% vs S&P 500 +18.1%; 5Y -75.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-16, EPS estimate USD -0.08, revenue estimate $0K.

## Analysts
Consensus Buy (mean 1.67 on a 1–5 scale), 6 analysts; mean target USD 4.17 (low 2.86, high 5.88).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-19 | HC Wainwright & Co. | Target lowered | Buy | $10 → $5 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -53.0% | -75.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -53.1% | -24.4% |
| Volatility (annualized) | 80.0% | 73.9% |
| Max drawdown | -63.0% (Jan 2026→Oct 2026) | -88.9% (Jul 2023→May 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/ONCY · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt